Hormonal contraception: What is new?

P. G. Crosignani, D. T. Baird, M. Bygdeman, E. Diczfalusy, T. Farley, A. Glasier, C. La Vecchia, D. Mishell, M. Oettel, S. Skouby, F. Wu, E. Arisi, J. Collins, G. C. Frigerio, K. Schmidt-Gollwitzer, A. Vople

Research output: Contribution to journalArticle

Abstract

Hormonal contraception has become more effective and more widely used, while the world population has grown from 3000 million in 1960 to 6000 million in 2000. There is a need for improved contraception, because legal abortion is used in a high proportion of pregnancies and illegal abortion continues to be common in some countries. Hormonal contraception now includes different choices of administration and dose regimens. The best selection depends on the benefits and risks of the method and whether there is a medical disability. Medical eligibility for combined oral contraceptives has improved during the past 40 years so that, for most women, all currently available low-dose products are safe. For women with medical conditions, wider eligibility for oral contraceptive use has evolved from better knowledge of the risk factors. The long-term risks of rare cardiovascular and malignant adverse events remain controversial. There are long-term benefits, however, as oral contraceptive use appears to protect against endometrial, ovarian and colorectal cancers. Emergency contraception provides an option that reduces the number of unplanned pregnancies with little or no long-term risk. Endometrial contraception is an option that would ideally have no influence on ovarian function or the bleeding pattern, and cause no significant side-effects. Hormonal male contraception, with indirect suppression of spermatogenesis by decreasing gonadotrophin output, is a further choice. Although hormonal contraception is effective and safe, many research investigations remain to be carried out in order to improve tolerance and achieve wider utilization.

Original languageEnglish
Pages (from-to)359-371
Number of pages13
JournalHuman Reproduction Update
Volume8
Issue number4
DOIs
Publication statusPublished - Jul 2002

Fingerprint

Contraception
Oral Contraceptives
Criminal Abortion
Unplanned Pregnancy
Legal Abortion
Contraceptives, Oral, Combined
Postcoital Contraception
Spermatogenesis
Endometrial Neoplasms
Gonadotropins
Ovarian Neoplasms
Colorectal Neoplasms
Hemorrhage
Pregnancy
Research
Population

Keywords

  • Demographic
  • Hormonal contraception
  • Long-term benefits
  • Long-term riks
  • Safety

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Crosignani, P. G., Baird, D. T., Bygdeman, M., Diczfalusy, E., Farley, T., Glasier, A., ... Vople, A. (2002). Hormonal contraception: What is new? Human Reproduction Update, 8(4), 359-371. https://doi.org/10.1093/humupd/8.4.359

Hormonal contraception : What is new? / Crosignani, P. G.; Baird, D. T.; Bygdeman, M.; Diczfalusy, E.; Farley, T.; Glasier, A.; La Vecchia, C.; Mishell, D.; Oettel, M.; Skouby, S.; Wu, F.; Arisi, E.; Collins, J.; Frigerio, G. C.; Schmidt-Gollwitzer, K.; Vople, A.

In: Human Reproduction Update, Vol. 8, No. 4, 07.2002, p. 359-371.

Research output: Contribution to journalArticle

Crosignani, PG, Baird, DT, Bygdeman, M, Diczfalusy, E, Farley, T, Glasier, A, La Vecchia, C, Mishell, D, Oettel, M, Skouby, S, Wu, F, Arisi, E, Collins, J, Frigerio, GC, Schmidt-Gollwitzer, K & Vople, A 2002, 'Hormonal contraception: What is new?', Human Reproduction Update, vol. 8, no. 4, pp. 359-371. https://doi.org/10.1093/humupd/8.4.359
Crosignani PG, Baird DT, Bygdeman M, Diczfalusy E, Farley T, Glasier A et al. Hormonal contraception: What is new? Human Reproduction Update. 2002 Jul;8(4):359-371. https://doi.org/10.1093/humupd/8.4.359
Crosignani, P. G. ; Baird, D. T. ; Bygdeman, M. ; Diczfalusy, E. ; Farley, T. ; Glasier, A. ; La Vecchia, C. ; Mishell, D. ; Oettel, M. ; Skouby, S. ; Wu, F. ; Arisi, E. ; Collins, J. ; Frigerio, G. C. ; Schmidt-Gollwitzer, K. ; Vople, A. / Hormonal contraception : What is new?. In: Human Reproduction Update. 2002 ; Vol. 8, No. 4. pp. 359-371.
@article{b64a956a5a4f46309fad5570b3f3ef86,
title = "Hormonal contraception: What is new?",
abstract = "Hormonal contraception has become more effective and more widely used, while the world population has grown from 3000 million in 1960 to 6000 million in 2000. There is a need for improved contraception, because legal abortion is used in a high proportion of pregnancies and illegal abortion continues to be common in some countries. Hormonal contraception now includes different choices of administration and dose regimens. The best selection depends on the benefits and risks of the method and whether there is a medical disability. Medical eligibility for combined oral contraceptives has improved during the past 40 years so that, for most women, all currently available low-dose products are safe. For women with medical conditions, wider eligibility for oral contraceptive use has evolved from better knowledge of the risk factors. The long-term risks of rare cardiovascular and malignant adverse events remain controversial. There are long-term benefits, however, as oral contraceptive use appears to protect against endometrial, ovarian and colorectal cancers. Emergency contraception provides an option that reduces the number of unplanned pregnancies with little or no long-term risk. Endometrial contraception is an option that would ideally have no influence on ovarian function or the bleeding pattern, and cause no significant side-effects. Hormonal male contraception, with indirect suppression of spermatogenesis by decreasing gonadotrophin output, is a further choice. Although hormonal contraception is effective and safe, many research investigations remain to be carried out in order to improve tolerance and achieve wider utilization.",
keywords = "Demographic, Hormonal contraception, Long-term benefits, Long-term riks, Safety",
author = "Crosignani, {P. G.} and Baird, {D. T.} and M. Bygdeman and E. Diczfalusy and T. Farley and A. Glasier and {La Vecchia}, C. and D. Mishell and M. Oettel and S. Skouby and F. Wu and E. Arisi and J. Collins and Frigerio, {G. C.} and K. Schmidt-Gollwitzer and A. Vople",
year = "2002",
month = "7",
doi = "10.1093/humupd/8.4.359",
language = "English",
volume = "8",
pages = "359--371",
journal = "Human Reproduction Update",
issn = "1355-4786",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Hormonal contraception

T2 - What is new?

AU - Crosignani, P. G.

AU - Baird, D. T.

AU - Bygdeman, M.

AU - Diczfalusy, E.

AU - Farley, T.

AU - Glasier, A.

AU - La Vecchia, C.

AU - Mishell, D.

AU - Oettel, M.

AU - Skouby, S.

AU - Wu, F.

AU - Arisi, E.

AU - Collins, J.

AU - Frigerio, G. C.

AU - Schmidt-Gollwitzer, K.

AU - Vople, A.

PY - 2002/7

Y1 - 2002/7

N2 - Hormonal contraception has become more effective and more widely used, while the world population has grown from 3000 million in 1960 to 6000 million in 2000. There is a need for improved contraception, because legal abortion is used in a high proportion of pregnancies and illegal abortion continues to be common in some countries. Hormonal contraception now includes different choices of administration and dose regimens. The best selection depends on the benefits and risks of the method and whether there is a medical disability. Medical eligibility for combined oral contraceptives has improved during the past 40 years so that, for most women, all currently available low-dose products are safe. For women with medical conditions, wider eligibility for oral contraceptive use has evolved from better knowledge of the risk factors. The long-term risks of rare cardiovascular and malignant adverse events remain controversial. There are long-term benefits, however, as oral contraceptive use appears to protect against endometrial, ovarian and colorectal cancers. Emergency contraception provides an option that reduces the number of unplanned pregnancies with little or no long-term risk. Endometrial contraception is an option that would ideally have no influence on ovarian function or the bleeding pattern, and cause no significant side-effects. Hormonal male contraception, with indirect suppression of spermatogenesis by decreasing gonadotrophin output, is a further choice. Although hormonal contraception is effective and safe, many research investigations remain to be carried out in order to improve tolerance and achieve wider utilization.

AB - Hormonal contraception has become more effective and more widely used, while the world population has grown from 3000 million in 1960 to 6000 million in 2000. There is a need for improved contraception, because legal abortion is used in a high proportion of pregnancies and illegal abortion continues to be common in some countries. Hormonal contraception now includes different choices of administration and dose regimens. The best selection depends on the benefits and risks of the method and whether there is a medical disability. Medical eligibility for combined oral contraceptives has improved during the past 40 years so that, for most women, all currently available low-dose products are safe. For women with medical conditions, wider eligibility for oral contraceptive use has evolved from better knowledge of the risk factors. The long-term risks of rare cardiovascular and malignant adverse events remain controversial. There are long-term benefits, however, as oral contraceptive use appears to protect against endometrial, ovarian and colorectal cancers. Emergency contraception provides an option that reduces the number of unplanned pregnancies with little or no long-term risk. Endometrial contraception is an option that would ideally have no influence on ovarian function or the bleeding pattern, and cause no significant side-effects. Hormonal male contraception, with indirect suppression of spermatogenesis by decreasing gonadotrophin output, is a further choice. Although hormonal contraception is effective and safe, many research investigations remain to be carried out in order to improve tolerance and achieve wider utilization.

KW - Demographic

KW - Hormonal contraception

KW - Long-term benefits

KW - Long-term riks

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0036653424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036653424&partnerID=8YFLogxK

U2 - 10.1093/humupd/8.4.359

DO - 10.1093/humupd/8.4.359

M3 - Article

C2 - 12206470

AN - SCOPUS:0036653424

VL - 8

SP - 359

EP - 371

JO - Human Reproduction Update

JF - Human Reproduction Update

SN - 1355-4786

IS - 4

ER -